NGS Methylation Detection System | Twist Bioscience

Comprehensive system for NGS methylation analysis combining enzymatic conversion, target enrichment, and high-performance methylation panels to identify methylated regions with greater efficiency, less DNA damage, and optimized sequencing metrics. The solution is designed for epigenetics, oncology, and the discovery of differentially methylated regions.

Detailed Description

Operating Principle

This is an end-to-end sample preparation and enrichment solution geared towards methylation analysis.

The workflow combines an enzymatic conversion of unmethylated cytosines, followed by capture-based enrichment using Twist probes and optimized hybridization reagents. Compared to chemical bisulfite treatment, this enzymatic approach is less harsh on DNA, requires less sample input, and generates higher quality libraries with better yield. Following PCR, the nucleotide representation is equivalent to that of bisulfite-treated DNA, allowing it to be integrated into established bioinformatics pipelines.

Twist methylation workflow

Clinical Applications

Geared towards methylation profiling applications in research related to cancer metastasis, human development, and functional genomics. Especially relevant in liquid biopsy studies due to its high compatibility with this type of samples. It can also be used for the identification of differentially methylated cytosines or regions (DMCs/DMRs) with potential functional, diagnostic, or prognostic value.

Benefits

The system stands out for providing a less damaging library preparation, with better mapping efficiency, higher GC uniformity, and overall improved sequencing metrics. In addition, it incorporates the Twist Methylation Enhancer, a specific blocker for post-conversion samples that reduces off-target capture by up to half without significantly affecting other metrics.

Technology Used

Compatible with broad commercial panels, targeted oncology panels, and custom solutions that fit the needs of each laboratory.
Twist Human Methylome Panel: 3.98M CpGs and 123 Mb of genomic content.
This panel identifies 84.2% of the genome’s CpG islands and significantly expands coverage compared to average microarrays, providing a greater capacity to analyze DMRs and adjacent regions.
Array comparison image
Twist Alliance Pan-cancer Panel: ~126,000 CpG sites, ~12,000 DMRs, 31 cancer types, and 47 TCGA entities. Custom panels

Intended Audience/User

Aimed at laboratories and groups specializing in epigenetics, molecular oncology, translational genomics, and NGS sequencing that need to study methylation in a targeted manner, with high capture efficiency and a less harsh alternative to bisulfite-based workflows.

Key Features

Comprehensive solution for targeted NGS methylation analysis with enzymatic conversion, capture enrichment, and optimized reagents.
Alternative to bisulfite with less DNA damage and better library quality.
Compatible with established bioinformatics analysis pipelines for methylation sequencing.
Possibility of incorporating custom panels to perform tailored studies.

Ordering Information

Preparation and enrichment reagents
103496 Library preparation and target enrichment reagents, 96 samples
Twist Human Methylome Panel
105517 2 captures
105520 12 captures
105521 96 captures
Other Panels
Inquire Twist Alliance Pan-cancer Methylation Panel

Area:

Epigenomics, Methylation studies by NGS, Molecular Genetics, Omics, Tumor Types
Consult our experts

Google reCaptcha: Invalid site key.

Related products

Franklin by QIAGEN for Somatic Analysis

Advanced cloud-based bioinformatics platform designed for the automated analysis, interpretation, and classification of somatic variants in oncology. Through an integrated environment, the system evaluates clinical evidence in real time, automates classification in accordance with AMP/ASCO/CAP guidelines, and provides access to currently active clinical trials. Detailed description Operating principle End-to-end cloud-based solution for the clinical interpretation…
Qiagen
Next Generation Sequencing (NGS)

SeqOne Genomics – Somatic

SeqOne is a bioinformatics platform for NGS data analysis in precision oncology, designed to detect, prioritise and interpret somatic variants and generate actionable clinical reports from raw sequencing data. It helps laboratories and healthcare professionals accelerate the interpretation of NGS data through an end-to-end workflow. Detailed description Operating principle SeqOne Genomics is a genomic data…
SeqOne
Next Generation Sequencing (NGS)

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

MSK-IMPACT® / MSK-IMPACT® FLEX

Decentralised, in-house comprehensive genomic profiling (CGP) solution for solid tumours, based on hybrid capture next-generation sequencing (NGS). Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it features a robust matched tumour-normal sequencing approach for filtering germline variants and clonal haematopoiesis. Detailed description Operating principle The decentralised MSK-IMPACT® powered with SOPHiA DDM™ solution enables…
SOPHIA Genetics
Next Generation Sequencing (NGS)